In the study by Shekarian et al., patients’ glioblastoma explant-based model was used to identify biomarkers of response to anti-CD47, anti–PD-1, or their combination in secretome of the explants, which required culturing in a perfusion bioreactor combined with highly multiplexed microscopy, soluble protein arrays, and mass spectrometry [19]. Here, CD47 is linked to glioblastoma.